comprehensive -WSS

comprehensive

author：fashion 2025-09-28 01:38:28 - browse：4892

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Clinical trials giant ICON acquires HumanFirst

WSS

White House Covid adviser calls on docs to combat misinformation

Senate bill would ban some hospital facility fees

Midwives could help bridge maternal health disparities in the U.S.

FogPharma raises $145 million in rare Series E round

The struggle to figure out which patients 'deserve' Wegovy

FDA weighs limits of animal data in assessing artificial wombs

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Continuity nursing helped my family in our darkest PICU moments

PBMs drew scrutiny in House hearing — and so did pharma

23andMe had bad news about my health. I wish a person had delivered it

FogPharma raises $145 million in rare Series E round

Moonlake's readout produced a cash windfall. Risks remain

PBMs drew scrutiny in House hearing — and so did pharma

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

International team creates first chimeric human

knowledge

Neurocrine congenital adrenal hyperplasia trial succeeds

Covid isolation guidance eased by the CDC

Patients, doctors press FTC to beef up hospital merger scrutiny

Why getting cancer drugs just got harder for rural patients

The unintended consequences of overturning Roe v. Wade

FDA panel to weigh safety of artificial wombs for preterm births

explore

focus

knowledge

knowledge